Loading
A phase 2 trial of Obinutuzumab, Glofitamab, Gemcitabine and Oxaliplatin in hodgkin lymphoma, run by Hoffmann-La Roche, now recruiting.
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL is a phase 2 interventional study registered as NCT06806033 by Hoffmann-La Roche, with 130 participants planned, started 2025-03-05 and due to reach its primary completion in 2027-01-31. Interventions recorded: Obinutuzumab, Glofitamab, Gemcitabine and Oxaliplatin.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Glofitamab, Flatiron Health (Roche), Obinutuzumab, T-cell engagers (bispecific) and the tag pipeline.
Shares Glofitamab, Flatiron Health (Roche), Obinutuzumab, T-cell engagers (bispecific) and the tag pipeline.
Shares Oxaliplatin, Gemcitabine, Platinum agents, Cytotoxic chemotherapy and the tag pipeline.
Shares Glofitamab, Flatiron Health (Roche), T-cell engagers (bispecific), Cytotoxic chemotherapy and the tag pipeline.
Shares Gemcitabine, Platinum agents, Cytotoxic chemotherapy and the tag pipeline.
Shares Glofitamab, Obinutuzumab and the tag pipeline.
Shares Oxaliplatin, Platinum agents, Cytotoxic chemotherapy and the tag pipeline.
Shares Oxaliplatin, Gemcitabine, Platinum agents, Cytotoxic chemotherapy and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/